https://www.pharmaceutical-technology.com/sponsored/top-three-trends-in-precision-medicine/ 2024-09-19T08:39:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gavi-bavarian-nordic-mpox-vaccine/ 2024-09-19T08:15:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-msd-keytruda/ 2024-09-19T08:07:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/leave-politics-out-of-healthcare-controversy-swirls-around-biosecure-act-2/ 2024-09-19T06:11:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-expands-novartis-kisqali-label-to-include-early-breast-cancer-patients/ 2024-09-18T15:41:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-eyes-teenage-label-for-chikungunya-vaccine-in-europe-and-canada/ 2024-09-18T14:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ossium-treats-leukaemia-patient-with-cryopreserved-bone-marrow/ 2024-09-19T17:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/japan-gsk-multiple-myeloma/ 2024-09-18T10:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/orbis-vivtex-macrocycle-drugs/ 2024-09-18T09:41:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beigene-tevimbra-approval-israel/ 2024-09-18T08:08:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nura-bio-funding-neuroprotective-therapies/ 2024-09-18T08:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/express-scripts-sues-ftc-and-demands-drug-pricing-report-retraction/ 2024-09-17T16:43:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-lifts-partial-clinical-hold-on-zentalis-pharmas-cancer-wee1-inhibitor/ 2024-09-17T16:04:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/equillium-collaborates-with-vivtex-for-oral-formulation-of-autoimmune-therapy/ 2024-09-17T15:50:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bicara-therapeutics-closes-362m-ipo-in-flurry-of-biotech-listing-activity/ 2024-09-17T12:59:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/podcast-how-drones-are-transforming-the-clinical-supply-chain-in-africa/ 2025-07-15T12:28:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-cuts-ties-immatics-bispecific-deal/ 2024-09-17T15:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rmat-poseida-car-t-bcma-allo1/ 2024-09-17T07:58:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/maxcyte-kamau-therapeutics-strategic-platform-licence/ 2024-09-17T07:32:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-shipping-beyfortus-us/ 2024-09-17T07:25:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sbti-piramal-pharmas-ghg-targets/ 2024-09-17T07:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esmo-2024-keytruda-is-key-to-first-line-treatment-of-her2-mgej-adenocarcinoma/ 2024-09-18T21:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win/ 2024-09-16T15:32:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/disease-modifiers-may-take-over-pah-landscape-says-cereno-ceo/ 2024-09-16T15:27:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss/ 2024-09-16T13:04:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/pioneering-epro-and-ecoa-innovations-for-next-generation-clinical-trials/ 2024-09-20T08:11:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-btd-blenrep-bordex-multiple-myeloma/ 2024-09-24T12:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-roche-ocrevus-zunovo/ 2024-09-16T10:29:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/after-the-lykos-debacle-whats-next-for-psychedelic-therapies/ 2024-09-17T12:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/minimizing-risks-in-pharmaceutical-supply-chains-what-you-need-to-know/ 2024-09-16T09:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-dupixent-crswnp/ 2024-09-16T08:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-ebglyss-fda-approval/ 2024-09-16T07:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteoss-tigit-in-nsclc/ 2024-09-16T01:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases/ 2024-10-16T11:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/japan-approves-updated-covid-19-vaccine-to-tackle-jn-1-variant/ 2024-09-13T17:45:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials/ 2024-09-13T16:12:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug/ 2024-09-13T13:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sobi-enable-injections-aspaveli/ 2024-09-13T10:16:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-roche-tecentriq-hybreza/ 2024-09-13T10:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/into-the-unknown-how-quickly-can-vaccines-be-developed-for-disease-x/ 2024-09-13T08:24:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-radioligand-therapy-deal/ 2024-09-13T08:19:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-invest-sites-ireland/ 2024-09-13T08:12:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-cuts-five-programmes-to-save-1-1bn-in-rd-costs/ 2024-09-12T15:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/easd-2024-innovent-shows-off-mazdutides-efficacy-in-diabetes-and-obesity/ 2024-09-12T15:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vermont-senator-introduces-bill-to-strengthen-340b-protections-for-drug-access/ 2024-09-12T15:34:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordic-promises-two-million-mpox-vaccines-for-africa-by-end-of-2024/ 2025-04-01T09:50:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/agios-tebapivat-fda-designation/ 2024-09-12T10:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/india-suspends-entod-licence-drops/ 2024-09-12T10:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-btd-neuraptive-ntx-001/ 2024-09-12T07:53:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnsons-tremfya-fda-approval/ 2024-09-12T07:48:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/easd-2024-tetra-agonists-future-metabolic-diseases-treatment/ 2024-09-17T20:44:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/iba-venture-pantera-gains-e134m-in-funding-to-scale-up-actinium-225-production/ 2024-09-11T15:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/easd2024-novo-nordisks-saxenda-shows-weight-loss-in-children/ 2024-09-11T13:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nanosyrinx-biologic-therapeutics/ 2024-09-11T10:12:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-breakthrough-therapy-status-plozasiran/ 2024-09-11T10:05:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-inaugurates-vaccine-plant-france/ 2024-09-11T07:57:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-genesis-partner-therapies-ai/ 2024-09-11T07:50:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects/ 2024-09-11T20:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/teva-agrees-to-pay-baltimore-city-80m-for-fuelling-opioid-epidemic/ 2024-09-10T19:29:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/easd2024-eli-lilly-releases-phase-iii-data-for-once-weekly-insulin-in-diabetes/ 2024-09-11T13:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-daiichis-adc-shows-better-survival-for-nonsquamous-nsclc-patients/ 2024-10-16T11:51:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/t-cell-targeting-candid-therapeutics-launches-with-370m/ 2024-09-10T16:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/easd-2024-novel-insights-into-maternal-protection-in-t1d/ 2024-09-10T14:04:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/easd-2024-new-developments-presymptomatic-type-1-diabetes-screening/ 2024-09-10T13:54:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-bill-chinese-biotech/ 2024-09-10T10:37:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/integrated-nanotherapeutics-secures-funds/ 2024-09-10T10:30:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vir-biotechnology-licence-deal-sanofi/ 2024-09-10T08:19:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-laval-facility-licence/ 2024-09-10T08:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/cmn-005-coimmune-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-10T01:06:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-09-10T01:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-10T01:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-10T01:06:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-10T01:05:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-10T01:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-10T01:05:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-follicular-lymphoma-likelihood-of-approval/ 2024-09-10T01:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-10T01:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sildenafil-citrate-xoma-royalty-female-hypoactive-sexual-desire-disorder-likelihood-of-approval/ 2024-09-10T01:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zaltenibart-omeros-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2024-09-10T01:04:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zaltenibart-omeros-kidney-disease-nephropathy-likelihood-of-approval/ 2024-09-10T01:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zaltenibart-omeros-glomerulonephritis-likelihood-of-approval/ 2024-09-10T01:03:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-innovent-biologics-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:52:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cosibelimab-checkpoint-therapeutics-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-09-10T01:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cosibelimab-checkpoint-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-09-10T01:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selpercatinib-loxo-oncology-sarcomas-likelihood-of-approval/ 2024-12-29T17:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cr-1301-conaris-research-institute-intestinal-infection-likelihood-of-approval/ 2024-09-10T01:01:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-merkel-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-angiosarcoma-likelihood-of-approval/ 2024-12-29T17:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-acral-lentiginous-melanoma-likelihood-of-approval/ 2024-12-29T17:52:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amdizalisib-hutchison-medipharma-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-29T17:52:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amdizalisib-hutchison-medipharma-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-10T01:00:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-10T00:59:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-10T00:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-solid-tumor-likelihood-of-approval/ 2024-09-10T00:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-liver-cancer-likelihood-of-approval/ 2024-09-10T00:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-09-10T00:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-09-10T00:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krls-004-kirilys-therapeutics-breast-cancer-likelihood-of-approval/ 2024-09-10T00:58:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allergen-for-house-dust-mite-induced-allergic-rhinitis-and-rhinoconjunctivitis-hal-allergy-allergic-rhinitis-likelihood-of-approval/ 2024-09-10T00:57:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpha-1-proteinase-inhibitor-human-second-generation-kamada-pharmaceuticals-alpha-1-antitrypsin-deficiency-a1ad-likelihood-of-approval-3/ 2024-12-29T17:52:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-29T17:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/alpha-1-proteinase-inhibitor-human-second-generation-kamada-pharmaceuticals-alpha-1-antitrypsin-deficiency-a1ad-likelihood-of-approval/ 2024-09-09T19:21:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mobocertinib-takeda-pharmaceutical-duodenal-cancer-likelihood-of-approval/ 2024-12-29T17:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:52:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mobocertinib-takeda-pharmaceutical-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mobocertinib-takeda-pharmaceutical-sarcomas-likelihood-of-approval/ 2024-12-29T17:52:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-merkel-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:51:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mobocertinib-takeda-pharmaceutical-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:52:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-papillary-thyroid-cancer-likelihood-of-approval/ 2024-12-29T17:51:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T17:51:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-29T17:51:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-follicular-thyroid-cancer-likelihood-of-approval/ 2024-12-29T17:51:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-salivary-gland-cancer-likelihood-of-approval/ 2024-12-29T17:51:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-vulvar-cancer-likelihood-of-approval/ 2024-12-29T17:51:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-solid-tumor-likelihood-of-approval/ 2024-12-29T17:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-melanoma-likelihood-of-approval/ 2024-12-29T17:51:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-sepsis-likelihood-of-approval/ 2024-12-29T17:51:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:51:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:51:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamvac-vlp-adaptvac-malaria-likelihood-of-approval/ 2024-09-09T19:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-447537-sanofi-emphysema-likelihood-of-approval/ 2024-09-09T19:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-priovant-therapeutics-intermediate-uveitis-likelihood-of-approval/ 2024-12-29T17:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teriparatide-corium-osteoporosis-likelihood-of-approval/ 2024-09-09T19:15:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ritlecitinib-pfizer-celiac-disease-likelihood-of-approval/ 2024-12-29T17:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-priovant-therapeutics-posterior-uveitis-likelihood-of-approval/ 2024-12-29T17:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stem-cell-therapy-for-bone-degeneration-and-cartilage-degeneration-bioinova-cartilage-degeneration-likelihood-of-approval/ 2024-09-09T19:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilparencel-prokidney-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-29T17:50:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mg1-maraba-turnstone-biologics-breast-cancer-likelihood-of-approval/ 2024-09-09T19:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mg1-maraba-turnstone-biologics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T19:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taletrectinib-adipate-nuvation-bio-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-adenovirus-type-5-recombinant-shanghai-sunway-biotech-malignant-ascites-likelihood-of-approval/ 2024-09-09T19:13:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/troriluzole-hydrochloride-biohaven-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:50:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ue-2343-actinogen-medical-major-depressive-disorder-likelihood-of-approval/ 2024-12-29T17:50:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-29T17:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/troriluzole-hydrochloride-biohaven-gliosarcoma-likelihood-of-approval/ 2024-09-09T19:12:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-solid-tumor-likelihood-of-approval/ 2024-12-29T17:50:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T17:50:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-bladder-cancer-likelihood-of-approval/ 2024-12-29T17:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:50:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-liver-cancer-likelihood-of-approval/ 2024-12-29T17:50:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-gastric-cancer-likelihood-of-approval/ 2024-12-29T17:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-prostate-cancer-likelihood-of-approval/ 2024-12-29T17:50:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-lung-cancer-likelihood-of-approval/ 2024-12-29T17:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annexuzlimab-medannex-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:50:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-round-cell-liposarcoma-likelihood-of-approval/ 2024-12-29T17:49:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allergen-for-pollen-grass-allergy-induced-allergic-rhinitis-and-rhinoconjunctivitis-hal-allergy-allergic-rhinitis-likelihood-of-approval/ 2024-09-09T19:09:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-12-29T17:49:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-myxoid-liposarcoma-likelihood-of-approval/ 2024-12-29T17:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chlorogenic-acid-sichuan-j-z-bio-chemical-science-and-technology-development-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:49:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-29T17:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-endometrial-cancer-likelihood-of-approval/ 2024-09-09T19:07:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trilaciclib-g1-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T19:07:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aav-aqp1-meiragtx-sicca-syndrome-sjogren-likelihood-of-approval/ 2024-09-09T19:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dnp-002-dinona-solid-tumor-likelihood-of-approval/ 2024-12-29T17:49:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hynr-cs-allo-corestemchemon-spinocerebellar-ataxia-sca-likelihood-of-approval/ 2024-09-09T19:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hynr-cs-allo-corestemchemon-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2024-09-09T19:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rezafungin-acetate-napp-pharmaceuticals-pneumocystis-pneumonia-pneumocystosis-pneumocystis-jiroveci-pneumonia-likelihood-of-approval/ 2024-09-09T19:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hynr-cs-allo-corestemchemon-cerebellar-ataxia-likelihood-of-approval/ 2024-09-09T19:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-8189-merck-schizophrenia-likelihood-of-approval/ 2024-09-09T19:05:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rezafungin-acetate-napp-pharmaceuticals-aspergillosis-likelihood-of-approval/ 2024-12-29T17:49:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986258-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T19:04:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltrekibart-eli-lilly-and-co-hidradenitis-suppurativa-likelihood-of-approval/ 2024-12-29T17:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T19:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-09-09T19:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-oxybate-er-avadel-pharmaceuticals-type-2-narcolepsy-narcolepsy-without-cataplexy-likelihood-of-approval/ 2024-12-29T17:49:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frexalimab-sanofi-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-29T17:49:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-alopecia-areata-likelihood-of-approval/ 2024-12-29T17:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-oxybate-er-avadel-pharmaceuticals-type-1-narcolepsy-narcolepsy-with-cataplexy-likelihood-of-approval/ 2024-12-29T17:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-for-gd2-expressing-solid-tumors-bellicum-pharmaceuticals-high-grade-glioma-likelihood-of-approval/ 2024-09-09T19:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-for-gd2-expressing-solid-tumors-bellicum-pharmaceuticals-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-09-09T19:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iscalimab-novartis-lupus-nephritis-likelihood-of-approval/ 2024-12-29T17:49:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-for-gd2-expressing-solid-tumors-bellicum-pharmaceuticals-medulloblastoma-likelihood-of-approval/ 2024-09-09T19:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-laurent-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2024-12-29T17:48:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iscalimab-novartis-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-29T17:48:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-testicular-cancer-likelihood-of-approval/ 2024-12-29T17:48:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaccine-for-central-nervous-system-cancer-immunomic-therapeutics-oligodendroglioma-likelihood-of-approval/ 2024-09-09T19:00:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-90002-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T19:00:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:48:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaccine-for-central-nervous-system-cancer-immunomic-therapeutics-anaplastic-astrocytoma-likelihood-of-approval/ 2024-09-09T18:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tislelizumab-beigene-gallbladder-cancer-likelihood-of-approval/ 2024-09-09T18:59:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/molgramostim-savara-lung-disease-likelihood-of-approval/ 2024-12-29T17:48:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-29T17:48:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medi-1814-astrazeneca-alzheimer-s-disease-likelihood-of-approval/ 2024-09-09T18:57:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:48:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acalabrutinib-maleate-astrazeneca-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-09-09T18:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acalabrutinib-maleate-astrazeneca-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T18:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pneumococcal-vaccine-cansino-biologics-streptococcal-pneumonia-likelihood-of-approval/ 2024-12-29T17:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acalabrutinib-maleate-astrazeneca-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T18:56:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/byon-4413-byondis-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T17:48:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/byon-4413-byondis-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T17:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/furestem-cd-kangstem-biotech-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-09-09T18:55:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/byon-4413-byondis-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-29T17:48:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T17:48:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sefaxersen-sodium-f-hoffmann-la-roche-geographic-atrophy-likelihood-of-approval/ 2024-09-09T18:55:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:48:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:47:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pamiparib-beigene-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:47:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-101-alector-mild-cognitive-impairment-likelihood-of-approval/ 2024-09-09T18:53:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-101-alector-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2024-09-09T18:53:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larotrectinib-sulfate-bayer-sarcomas-likelihood-of-approval/ 2024-12-29T17:47:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entrectinib-f-hoffmann-la-roche-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:47:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:47:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-29T17:47:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:47:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T18:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-09-09T18:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-09-09T18:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-endometrial-cancer-likelihood-of-approval/ 2024-09-09T18:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T18:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-bladder-cancer-likelihood-of-approval/ 2024-09-09T18:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:47:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-ovarian-cancer-likelihood-of-approval/ 2024-09-09T18:49:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-viral-central-memory-cd8-veto-cells-cell-source-sickle-cell-disease-likelihood-of-approval/ 2024-12-29T17:47:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afabicin-debiopharm-international-osteomyelitis-likelihood-of-approval/ 2024-09-09T18:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:47:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elraglusib-actuate-therapeutics-neuroblastoma-likelihood-of-approval/ 2024-12-29T17:47:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-high-grade-glioma-likelihood-of-approval/ 2024-12-29T17:47:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-anaplastic-oligoastrocytoma-likelihood-of-approval/ 2024-12-29T17:47:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-oligodendroglioma-likelihood-of-approval/ 2024-12-29T17:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-gliosarcoma-likelihood-of-approval/ 2024-09-09T18:47:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/citarinostat-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:46:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-29T17:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-metastatic-breast-cancer-likelihood-of-approval/ 2024-09-09T18:46:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/citarinostat-bristol-myers-squibb-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-12-29T17:46:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caly-002-novartis-celiac-disease-likelihood-of-approval/ 2024-12-29T17:46:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caly-002-novartis-eosinophilic-esophagitis-likelihood-of-approval/ 2024-12-29T17:46:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-duocarmazine-byondis-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:46:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iadademstat-oryzon-genomics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-09-09T18:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volixibat-potassium-mirum-pharmaceuticals-primary-sclerosing-cholangitis-likelihood-of-approval/ 2024-12-29T17:46:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-duocarmazine-byondis-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-endometrial-cancer-likelihood-of-approval/ 2024-09-09T18:43:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volixibat-potassium-mirum-pharmaceuticals-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2024-12-29T17:46:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-ovarian-cancer-likelihood-of-approval/ 2024-09-09T18:43:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-cervical-cancer-likelihood-of-approval/ 2024-09-09T18:43:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adct-701-adc-therapeutics-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-09-09T18:42:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adct-701-adc-therapeutics-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2024-09-09T18:42:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-588410-shionogi-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T18:42:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-bullous-pemphigoid-likelihood-of-approval/ 2024-12-29T17:46:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endoxifen-jina-pharmaceuticals-bipolar-i-disorder-likelihood-of-approval/ 2024-12-29T17:46:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rebonuputemcel-discgenics-degenerative-disc-disease-likelihood-of-approval/ 2024-12-29T17:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aminolevulinic-acid-hydrochloride-photonamic-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:46:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aminolevulinic-acid-hydrochloride-photonamic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-angiosarcoma-likelihood-of-approval/ 2024-12-29T17:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulotaront-hydrochloride-otsuka-pharmaceutical-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2024-09-09T18:40:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/capsulin-oad-diabetology-products-type-2-diabetes-likelihood-of-approval/ 2024-09-09T18:39:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jm-010-contera-pharma-dyskinesia-likelihood-of-approval/ 2024-09-09T18:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/upadacitinib-er-abbvie-giant-cell-arteritis-temporal-arteritis-cranial-arteritis-horton-disease-likelihood-of-approval/ 2024-12-29T17:45:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimitespib-otsuka-pharmaceutical-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:45:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimitespib-otsuka-pharmaceutical-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:45:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimitespib-otsuka-pharmaceutical-bladder-cancer-likelihood-of-approval/ 2024-12-29T17:45:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimitespib-otsuka-pharmaceutical-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:45:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/umbralisib-tosylate-tg-therapeutics-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-09-09T18:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/umbralisib-tosylate-tg-therapeutics-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-09-09T18:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emicizumab-chugai-pharmaceutical-von-willebrand-disease-vwd-likelihood-of-approval/ 2024-09-09T18:36:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpmx-1-lipomedix-pharmaceutical-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:45:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-vaginal-cancer-likelihood-of-approval/ 2024-12-29T17:45:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-vulvar-cancer-likelihood-of-approval/ 2024-12-29T17:45:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-hydrochloride-innopharmax-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:45:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-anal-cancer-likelihood-of-approval/ 2024-12-29T17:45:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hk-660s-curome-bioscience-melas-syndrome-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-likelihood-of-approval/ 2024-09-09T18:34:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jpi-289-jeil-pharmaceutical-myocardial-infarction-likelihood-of-approval/ 2024-12-29T17:45:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fitusiran-sanofi-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-09-09T18:34:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fitusiran-sanofi-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2024-09-09T18:34:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-12-29T17:45:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapansutrile-olatec-therapeutics-type-2-diabetes-likelihood-of-approval/ 2024-12-29T17:45:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-12-29T17:45:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-malignant-pleural-mesothelioma-likelihood-of-approval/ 2024-12-29T17:45:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T17:44:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-12-29T17:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:44:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T18:31:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fasudil-woolsey-pharmaceuticals-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-12-29T17:44:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T17:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narmafotinib-amplia-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/leuprorelin-sr-foresee-pharmaceuticals-central-precocious-puberty-likelihood-of-approval/ 2024-09-09T18:30:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/batoclimab-immunovant-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2024-12-29T17:44:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medi-0457-astrazeneca-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2024-12-29T17:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iopofosine-i-131-cellectar-biosciences-secondary-cns-lymphoma-likelihood-of-approval/ 2024-12-29T17:44:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idasanutlin-f-hoffmann-la-roche-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-12-29T17:44:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chikv-vlp-bavarian-nordic-chikungunya-fever-likelihood-of-approval/ 2024-12-29T17:44:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iopofosine-i-131-cellectar-biosciences-primary-cns-lymphoma-likelihood-of-approval/ 2024-12-29T17:44:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-thymic-carcinoma-likelihood-of-approval/ 2024-12-29T17:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/satralizumab-f-hoffmann-la-roche-myasthenia-gravis-likelihood-of-approval/ 2024-09-09T18:28:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/usmarapride-suven-life-sciences-cognitive-disorders-likelihood-of-approval/ 2024-12-29T17:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/calaspargase-pegol-les-laboratoires-servier-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T18:27:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-vulvar-cancer-likelihood-of-approval/ 2024-12-29T17:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/usmarapride-suven-life-sciences-alzheimer-s-disease-likelihood-of-approval/ 2024-12-29T17:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T17:43:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-vaginal-cancer-likelihood-of-approval/ 2024-12-29T17:43:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/testosterone-m-et-p-pharma-male-hypogonadism-likelihood-of-approval/ 2024-09-09T18:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemcentinib-bergenbio-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T17:43:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimegepant-sulfate-odt-pfizer-abdominal-pain-likelihood-of-approval/ 2024-12-29T17:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexmarilimab-faron-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2024-12-29T17:43:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadomide-hydrochloride-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:43:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimegepant-sulfate-odt-pfizer-irritable-bowel-syndrome-likelihood-of-approval/ 2024-09-09T18:24:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcn-01-theriva-biologics-high-grade-glioma-likelihood-of-approval/ 2024-12-29T17:43:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadomide-hydrochloride-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:43:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ubidecarenone-bpgbio-sarcopenia-likelihood-of-approval/ 2024-12-29T17:43:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kos-1803-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:43:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-inflammatory-myofibroblastic-tumor-imt-likelihood-of-approval/ 2024-09-09T18:23:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prv-3279-sanofi-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-29T17:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-central-nervous-system-cns-tumor-likelihood-of-approval-2/ 2024-12-29T17:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-high-grade-glioma-likelihood-of-approval/ 2024-12-29T17:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solriamfetol-hydrochloride-axsome-therapeutics-fatigue-likelihood-of-approval/ 2024-12-29T17:42:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:43:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/alectinib-f-hoffmann-la-roche-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-09-09T18:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pan-cancer-t-looks-to-increase-t-cell-durability-with-next-gen-tcr-t/ 2024-09-11T13:42:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/summits-checkpoint-inhibitor-trumps-keytruda-in-lung-cancer-trial/ 2024-09-09T16:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/easd2024-poltregs-t-cell-therapy-shows-long-term-remission-in-type-1-diabetes/ 2024-09-11T13:06:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/microbiome-market-new-frontiers/ 2024-09-09T12:13:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunovant-touts-positive-phase-ii-batoclimab-data-as-imvt-1402-also-progresses/ 2024-09-09T12:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/formosa-ophthalmic-drug-us/ 2024-09-09T10:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/epsilogen-cancer-treatment/ 2024-09-09T10:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sun-pharma-moebius-osteoarthritis-treatment/ 2024-09-09T09:08:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/orsobio-obesity-treatment-portfolio/ 2024-09-09T09:00:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-115-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:42:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifetroban-cumberland-pharmaceuticals-asthma-likelihood-of-approval/ 2024-12-29T17:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rescap-alloksys-life-sciences-burns-likelihood-of-approval/ 2024-12-29T17:42:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-115-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T08:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-aplastic-anemia-likelihood-of-approval/ 2024-12-29T17:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-secondary-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T17:42:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xentuzumab-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:42:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:42:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-813160-bristol-myers-squibb-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T17:42:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-813160-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:42:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-anaplastic-thyroid-cancer-likelihood-of-approval/ 2024-12-29T17:42:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utomilumab-pfizer-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T17:42:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-hepatocellular-carcinoma-likelihood-of-approval/ 2024-12-29T17:42:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:42:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-head-and-neck-cancer-likelihood-of-approval/ 2024-12-29T17:42:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:42:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-melanoma-likelihood-of-approval/ 2024-12-29T17:41:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:41:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foscenvivint-eisai-prostate-cancer-likelihood-of-approval/ 2024-12-29T17:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabiralizumab-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T08:10:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ondansetron-hydrochloride-adial-pharmaceuticals-alcohol-dependence-likelihood-of-approval/ 2024-12-29T17:41:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabiralizumab-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-09-09T08:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986360-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T08:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydromethylthionine-mesylate-taurx-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2024-12-29T17:41:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986360-bristol-myers-squibb-sarcomas-likelihood-of-approval/ 2024-09-09T08:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talazoparib-pfizer-bladder-cancer-likelihood-of-approval/ 2024-12-29T17:41:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-quince-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-09-09T08:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-gastrointestinal-tumor-likelihood-of-approval/ 2024-12-29T17:41:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-neuroendocrine-tumors-likelihood-of-approval/ 2024-12-29T17:41:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-284-vistagen-therapeutics-cachexia-likelihood-of-approval/ 2024-09-09T08:07:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maraviroc-gsk-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2024-12-29T17:41:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immune-globulin-human-csl-traumatic-spinal-cord-injury-likelihood-of-approval/ 2024-09-09T08:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asparaginase-erwinia-chrysanthemi-porton-biopharma-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-12-29T17:41:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T08:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T08:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2024-09-09T08:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T08:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-melanoma-likelihood-of-approval/ 2024-09-09T08:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-09-09T08:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pitolisant-hydrochloride-harmony-biosciences-cognitive-impairment-likelihood-of-approval/ 2024-12-29T17:41:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pitolisant-hydrochloride-harmony-biosciences-myotonic-dystrophy-likelihood-of-approval/ 2024-12-29T17:41:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/romidepsin-bristol-myers-squibb-thyroid-cancer-likelihood-of-approval/ 2024-12-29T17:41:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pitolisant-hydrochloride-harmony-biosciences-fatigue-likelihood-of-approval/ 2024-12-29T17:41:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-alfasigma-immunoglobulin-g4-related-disease-igg4-rd-likelihood-of-approval/ 2024-12-29T17:40:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/romidepsin-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-alfasigma-behcet-disease-likelihood-of-approval/ 2024-12-29T17:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-alfasigma-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2024-12-29T17:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:40:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immuncell-lc-gc-cell-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T08:01:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-metastatic-uveal-melanoma-likelihood-of-approval/ 2024-12-29T17:40:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fostamatinib-disodium-rigel-pharmaceuticals-hidradenitis-suppurativa-likelihood-of-approval/ 2024-12-29T17:40:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-12-29T17:40:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-29T17:40:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-ono-pharmaceutical-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:40:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipp-204106-immupharma-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T07:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-t-cell-lymphomas-likelihood-of-approval/ 2024-12-29T17:40:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pomalidomide-bristol-myers-squibb-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:40:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alirocumab-regeneron-pharmaceuticals-sepsis-likelihood-of-approval/ 2024-09-09T07:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olvimulogene-nanivacirepvec-genelux-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2024-12-29T17:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hil-214-hillevax-gastroenteritis-likelihood-of-approval/ 2024-09-09T07:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-29T17:39:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olvimulogene-nanivacirepvec-genelux-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensartinib-hydrochloride-betta-pharmaceuticals-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-12-29T17:39:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T07:57:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lactin-v-osel-human-papillomavirus-infections-likelihood-of-approval/ 2024-12-29T17:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensartinib-hydrochloride-betta-pharmaceuticals-sarcomas-likelihood-of-approval/ 2024-12-29T17:39:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadisegliatin-vtv-therapeutics-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-09-09T07:55:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lactin-v-osel-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:39:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-synovial-sarcoma-likelihood-of-approval/ 2024-12-29T17:39:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:39:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-12-29T17:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-29T17:39:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2024-12-29T17:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-renal-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:39:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:39:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:39:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-29T17:39:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-gastric-cancer-likelihood-of-approval/ 2024-12-29T17:39:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T17:39:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siplizumab-itb-med-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-09-09T07:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-papillomavirus-virus-like-particle-9-valent-vaccine-merck-human-papillomavirus-infections-likelihood-of-approval/ 2024-09-09T07:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vpm-1002-serum-institute-of-india-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disufenton-sodium-oblato-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-09-09T07:51:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:38:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vpm-1002-serum-institute-of-india-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-12-29T17:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-12-29T17:38:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T07:49:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gimatecan-lee-s-pharmaceutical-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T07:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gimatecan-lee-s-pharmaceutical-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T07:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirdametinib-springworks-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:38:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirdametinib-springworks-therapeutics-neurofibromatoses-type-i-von-recklinghausen-s-disease-likelihood-of-approval/ 2024-12-29T17:38:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-731-immutep-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-09-09T07:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-hidradenitis-suppurativa-likelihood-of-approval/ 2024-12-29T17:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/n-115-emphycorp-allergic-rhinitis-likelihood-of-approval/ 2024-09-09T07:47:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-hematological-tumor-likelihood-of-approval/ 2024-12-29T17:38:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asunercept-apogenix-solid-tumor-likelihood-of-approval/ 2024-12-29T17:38:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asunercept-apogenix-hematological-tumor-likelihood-of-approval/ 2024-12-29T17:38:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabedersen-sapu-bioscience-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T17:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T17:38:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaptesed-pegol-tme-pharma-glioblastoma-multiforme-gbm-likelihood-of-approval-4/ 2024-12-29T17:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabedersen-sapu-bioscience-solid-tumor-likelihood-of-approval/ 2024-09-09T07:45:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivaltinostat-cg-invites-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-29T17:38:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivaltinostat-cg-invites-alport-syndrome-likelihood-of-approval/ 2024-12-29T17:38:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivaltinostat-cg-invites-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-12-29T17:37:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivaltinostat-cg-invites-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-29T17:38:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ripasudil-hydrochloride-hydrate-kowa-fuchs-endothelial-corneal-dystrophy-fecd-likelihood-of-approval/ 2024-12-29T17:37:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revakinagene-taroretcel-neurotech-pharmaceuticals-idiopathic-juxtafoveolar-retinal-telangiectasis-ijrt-likelihood-of-approval/ 2024-09-09T07:44:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensifentrine-verona-pharma-chronic-asthma-likelihood-of-approval/ 2024-12-29T17:37:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensifentrine-verona-pharma-allergic-asthma-likelihood-of-approval/ 2024-12-29T17:37:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narazaciclib-traws-pharma-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:37:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensifentrine-verona-pharma-cystic-fibrosis-likelihood-of-approval/ 2024-12-29T17:37:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:37:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narazaciclib-traws-pharma-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:37:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naxitamab-y-mabs-therapeutics-ewing-sarcoma-likelihood-of-approval/ 2024-12-29T17:37:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipiracil-hydrochloride-trifluridine-taiho-oncology-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-12-29T17:37:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-les-laboratoires-servier-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:37:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plogosertib-cyclacel-pharmaceuticals-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-12-29T17:37:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-12-29T17:37:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:37:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bremelanotide-acetate-cosette-pharmaceuticals-obesity-likelihood-of-approval/ 2024-09-09T07:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endostatin-simcere-pharmaceutical-group-nasopharyngeal-cancer-likelihood-of-approval/ 2024-09-09T07:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rintatolimod-aim-immunotech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:36:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-mucopolysaccharidosis-iii-mps-iii-sanfilippo-syndrome-likelihood-of-approval/ 2024-12-29T17:37:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eculizumab-alexion-pharmaceuticals-subarachnoid-hemorrhage-likelihood-of-approval/ 2024-12-29T17:36:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruxolitinib-phosphate-novartis-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T17:36:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-leiomyosarcoma-likelihood-of-approval/ 2024-12-29T17:35:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zotiraciclib-citrate-beijing-zhikangbo-medical-oncology-research-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dasatinib-bristol-myers-squibb-breast-cancer-likelihood-of-approval/ 2024-12-29T17:35:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pexastimogene-devacirepvec-sillajen-biotherapeutics-prostate-cancer-likelihood-of-approval/ 2024-12-29T17:35:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapirolizumab-pegol-ucb-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-29T17:34:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldoxorubicin-ladrx-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T07:37:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/devimistat-cornerstone-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:34:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bilastine-faes-farma-allergic-conjunctivitis-likelihood-of-approval/ 2024-09-09T07:36:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T17:34:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elafibranor-ipsen-primary-sclerosing-cholangitis-likelihood-of-approval/ 2024-12-29T17:34:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-f-hoffmann-la-roche-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:34:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-29T17:34:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obicetrapib-calcium-newamsterdam-pharma-company-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval/ 2024-12-29T17:34:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seladelpar-lysine-gilead-sciences-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2024-09-09T07:34:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:34:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-12-29T17:34:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotagliflozin-lexicon-pharmaceuticals-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-09-09T07:33:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:34:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T17:34:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:34:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T17:33:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-high-grade-glioma-likelihood-of-approval/ 2024-12-29T17:33:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-oligodendroglioma-likelihood-of-approval/ 2024-12-29T17:33:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-gliosarcoma-likelihood-of-approval/ 2024-12-29T17:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-anaplastic-astrocytoma-likelihood-of-approval/ 2024-12-29T17:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:33:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-12-29T17:33:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mocetinostat-bristol-myers-squibb-rhabdomyosarcoma-likelihood-of-approval/ 2024-09-09T07:29:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T17:33:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remestemcel-l-mesoblast-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-12-29T17:33:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mocetinostat-bristol-myers-squibb-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T07:29:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-12-29T17:33:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daprodustat-gsk-anemia-in-chronic-kidney-disease-renal-anemia-likelihood-of-approval/ 2024-09-09T07:28:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-myelofibrosis-likelihood-of-approval/ 2024-12-29T17:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-12-29T17:33:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-juvenile-myelomonocytic-leukemia-jmml-likelihood-of-approval/ 2024-12-29T17:32:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2024-12-29T17:33:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lupus-nephritis-likelihood-of-approval-2/ 2024-12-29T17:32:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-antiphospholipid-syndrome-likelihood-of-approval/ 2024-12-29T17:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vicriviroc-merck-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T07:26:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/benralizumab-astrazeneca-rhinosinusitis-likelihood-of-approval/ 2024-09-09T07:26:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2024-12-29T17:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/collagenase-clostridium-histolyticum-endo-international-benign-tumor-likelihood-of-approval/ 2024-09-09T07:25:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T17:32:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-29T17:32:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tbo-309-astrazeneca-acute-ischemic-stroke-likelihood-of-approval/ 2024-09-09T07:24:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-pfizer-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:32:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-09-09T07:24:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volagidemab-remd-biotherapeutics-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-12-29T17:32:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval-2/ 2024-09-09T07:23:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2024-09-09T07:23:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:32:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-12-29T17:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/ixazomib-citrate-millennium-pharmaceuticals-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-09-09T07:22:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vortioxetine-hydrobromide-h-lundbeck-bipolar-disorder-manic-depression-likelihood-of-approval/ 2024-12-29T17:32:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-metastatic-uveal-melanoma-likelihood-of-approval/ 2024-12-29T17:32:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-uveal-melanoma-likelihood-of-approval/ 2024-12-29T17:32:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/namilumab-izana-bioscience-ankylosing-spondylitis-bekhterev-s-disease-likelihood-of-approval/ 2024-09-09T07:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-12-29T17:31:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-acral-lentiginous-melanoma-likelihood-of-approval/ 2024-12-29T17:32:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/namilumab-izana-bioscience-axial-spondyloarthritis-likelihood-of-approval/ 2024-09-09T07:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dmt-310-dermata-therapeutics-psoriasis-likelihood-of-approval/ 2024-09-09T06:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/b-244-aobiome-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-09-09T05:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cenegermin-dompe-farmaceutici-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-21T16:58:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quaratusugene-ozeplasmid-genprex-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naxitamab-y-mabs-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T05:57:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amantadine-hydrochloride-shinkei-therapeutics-traumatic-brain-injury-likelihood-of-approval/ 2024-09-09T05:55:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-1001-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:55:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-09-09T05:54:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-t-cell-lymphomas-likelihood-of-approval/ 2024-09-09T05:53:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-09-09T05:53:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-t-cell-leukemia-likelihood-of-approval/ 2024-09-09T05:53:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mer-3101-mercia-pharma-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-09-09T05:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2024-botanical-solution/ 2025-01-22T07:45:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chenodiol-mirum-pharmaceuticals-cerebrotendinous-xanthomatosis-likelihood-of-approval/ 2024-09-09T04:25:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jte-162-japan-tobacco-inflammation-likelihood-of-approval-2/ 2025-01-20T16:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jte-162-japan-tobacco-autoimmune-disorders-likelihood-of-approval-2/ 2025-01-20T16:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mar-001-marea-therapeutics-hypertriglyceridemia-likelihood-of-approval-2/ 2024-09-09T04:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-129-nanjing-iaso-biotherapeutics-autoimmune-disorders-likelihood-of-approval-2/ 2024-09-09T04:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/interferon-alfa-2b-center-for-genetic-engineering-and-biotechnology-genital-warts-condylomata-acuminata-likelihood-of-approval-2/ 2024-09-09T04:18:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-dp-qurgen-metastatic-colorectal-cancer-likelihood-of-approval-3/ 2024-09-09T04:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-dp-qurgen-metastatic-ovarian-cancer-likelihood-of-approval-2/ 2024-09-09T04:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-dp-qurgen-metastatic-breast-cancer-likelihood-of-approval-2/ 2024-09-09T04:16:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-dp-qurgen-metastatic-pancreatic-cancer-likelihood-of-approval-2/ 2024-09-09T04:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/son-dp-qurgen-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-09-09T04:07:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmx-2043-ischemix-traumatic-brain-injury-likelihood-of-approval-2/ 2024-09-09T03:31:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-nk-101-wugen-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-09-09T03:29:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-nk-101-wugen-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-09-09T03:29:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbs-007-lin-bioscience-myelodysplastic-syndrome-likelihood-of-approval-2/ 2024-09-09T03:27:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbs-007-lin-bioscience-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval-2/ 2024-09-09T03:27:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cj-15314-hk-inno-n-rheumatoid-arthritis-likelihood-of-approval-2/ 2024-09-09T03:26:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/safinamide-mesylate-zambon-co-drug-induced-dyskinesia-likelihood-of-approval-3/ 2024-09-09T03:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/safinamide-mesylate-zambon-co-drug-induced-dyskinesia-likelihood-of-approval-2/ 2024-09-09T02:29:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonidegib-phosphate-sun-pharma-advanced-research-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-09-09T02:28:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/br-6002-boryung-pharmaceutical-duodenal-ulcer-likelihood-of-approval-2/ 2024-09-09T02:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/br-6002-boryung-pharmaceutical-cardiovascular-disease-likelihood-of-approval-2/ 2024-09-09T02:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/br-6002-boryung-pharmaceutical-gastric-ulcers-likelihood-of-approval-2/ 2024-09-09T02:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mnv-201-minovia-therapeutics-subacute-necrotizing-encephalomyelopathy-leigh-disease-likelihood-of-approval/ 2024-09-09T02:26:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mnv-201-minovia-therapeutics-pearson-syndrome-likelihood-of-approval/ 2025-01-19T18:26:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-07-sentinel-oncology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T02:25:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-07-sentinel-oncology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T02:25:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pep-07-sentinel-oncology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:25:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/streptococcus-vaccine-minervax-streptococcal-infections-likelihood-of-approval/ 2025-01-19T18:21:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cj-15314-hk-inno-n-psoriasis-likelihood-of-approval-2/ 2024-09-09T02:18:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yr-001-yirui-pharmaceutical-technology-atopic-dermatitis-atopic-eczema-likelihood-of-approval-2/ 2024-09-09T02:17:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yr-001-yirui-pharmaceutical-technology-psoriasis-likelihood-of-approval-2/ 2024-09-09T02:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-alkem-laboratories-oral-cavity-mouth-cancer-likelihood-of-approval-2/ 2024-09-09T02:14:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-alkem-laboratories-lip-cancer-likelihood-of-approval-2/ 2024-09-09T02:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-alkem-laboratories-pharyngeal-neoplasm-likelihood-of-approval-2/ 2024-09-09T02:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biosimilar-alkem-laboratories-locally-recurrent-or-locoregional-solid-malignancies-likelihood-of-approval-2/ 2024-09-09T02:13:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memant-3310-antabio-enterobacteriaceae-infections-likelihood-of-approval-2/ 2024-09-09T02:11:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memant-3310-antabio-acinetobacter-infections-likelihood-of-approval-3/ 2024-09-09T02:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/memant-3310-antabio-acinetobacter-infections-likelihood-of-approval-2/ 2024-09-09T02:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emicizumab-chugai-pharmaceutical-acquired-hemophilia-a-likelihood-of-approval-2/ 2024-09-09T01:57:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clv-100-cytopeutics-graft-versus-host-disease-gvhd-likelihood-of-approval-2/ 2025-01-19T17:42:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crn-04894-crinetics-pharmaceuticals-congenital-adrenal-hyperplasia-adrenogenital-syndrome-likelihood-of-approval/ 2024-09-09T01:53:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gefurulimab-alexion-pharmaceuticals-myasthenia-gravis-likelihood-of-approval-2/ 2024-09-09T01:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elsubrutinib-abbvie-systemic-lupus-erythematosus-likelihood-of-approval-2/ 2024-09-09T01:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/knx-100-kinoxis-therapeutics-opium-opioid-addiction-likelihood-of-approval-2/ 2025-01-19T16:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fr-104-veloxis-pharmaceuticals-kidney-transplant-rejection-likelihood-of-approval-2/ 2024-09-09T01:38:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diazoxide-choline-cr-soleno-therapeutics-net-present-value-2/ 2024-12-13T03:07:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hil-214-hillevax-net-present-value-2/ 2024-09-08T18:42:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirdametinib-springworks-therapeutics-net-present-value-3/ 2024-12-13T03:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedatolisib-celcuity-net-present-value-3/ 2024-12-13T03:07:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-net-present-value-2/ 2024-12-13T03:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izokibep-acelyrin-net-present-value-2/ 2024-12-13T03:07:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-net-present-value-2/ 2024-12-13T03:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-201-tenaya-therapeutics-net-present-value-2/ 2024-12-13T03:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neffy-ars-pharmaceuticals-net-present-value-4/ 2024-09-08T18:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/myk-224-bristol-myers-squibb-net-present-value-2/ 2024-12-13T03:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dordaviprone-chimerix-net-present-value-3/ 2024-12-13T03:06:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opc-1-lineage-cell-therapeutics-net-present-value-2/ 2024-12-13T03:06:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4178116a-gsk-net-present-value-2/ 2024-12-13T03:06:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgls-8429-regulus-therapeutics-net-present-value-2/ 2024-12-13T03:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-net-present-value-2/ 2024-12-13T03:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-1284-intra-cellular-therapies-net-present-value-2/ 2024-12-13T03:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-syndax-pharmaceuticals-net-present-value-2/ 2024-12-13T03:06:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afimetoran-bristol-myers-squibb-net-present-value-2/ 2024-12-13T03:06:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozuriftamab-vedotin-bioatla-net-present-value-2/ 2024-12-13T03:06:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vesigel-urogen-pharma-net-present-value-2/ 2024-12-13T03:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavdegalutamide-arvinas-net-present-value-2/ 2024-12-13T03:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/laronidase-jcr-pharmaceuticals-net-present-value-3/ 2024-12-13T03:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tildacerfont-spruce-biosciences-net-present-value-2/ 2024-09-08T18:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sebetralstat-kalvista-pharmaceuticals-net-present-value-2/ 2024-12-13T03:06:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ixoberogene-soroparvovec-adverum-biotechnologies-net-present-value-3/ 2024-12-13T03:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-ocular-therapeutix-net-present-value-2/ 2024-12-13T03:06:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-net-present-value-3/ 2024-12-13T03:06:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trotabresib-bristol-myers-squibb-net-present-value-2/ 2024-12-13T03:05:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-iteos-therapeutics-net-present-value-2/ 2024-12-13T03:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecbotamab-vedotin-bioatla-net-present-value-2/ 2024-12-13T03:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galinpepimut-s-sellas-life-sciences-group-net-present-value-2/ 2024-09-08T18:33:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/treprostinil-palmitil-insmed-net-present-value-3/ 2024-12-13T03:05:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aav-aqp1-meiragtx-net-present-value-2/ 2024-12-13T03:05:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobolimab-gsk-net-present-value-3/ 2024-12-13T03:05:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iscalimab-novartis-net-present-value-3/ 2024-12-13T03:05:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vimseltinib-deciphera-pharmaceuticals-net-present-value-3/ 2024-09-08T18:32:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/molgradex-savara-net-present-value-2/ 2024-12-13T03:05:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemvidutide-altimmune-net-present-value-2/ 2024-12-13T03:05:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rocatinlimab-amgen-net-present-value-2/ 2024-12-13T03:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/batoclimab-immunovant-net-present-value-3/ 2024-12-13T03:05:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1070770-neurocrine-biosciences-net-present-value/ 2024-12-13T03:05:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6341-roche-net-present-value/ 2024-12-13T03:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shr-1905-gsk-net-present-value/ 2024-12-13T03:05:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3739937-gsk-net-present-value/ 2024-12-13T03:05:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/divarasib-roche-net-present-value/ 2024-12-13T03:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065890-neurocrine-biosciences-net-present-value/ 2024-12-13T03:05:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bempikibart-q32-bio-net-present-value/ 2024-12-13T03:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pmuc1callo-1-poseida-therapeutics-net-present-value/ 2024-12-13T03:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/flt-201-spur-therapeutics-net-present-value-2/ 2024-12-13T03:04:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tobemstomig-roche-net-present-value/ 2024-12-13T03:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trontinemab-roche-net-present-value/ 2024-12-13T03:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amelenodor-abbvie-net-present-value/ 2024-12-13T03:04:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oric-533-oric-pharmaceuticals-net-present-value/ 2024-12-13T03:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6237-roche-net-present-value/ 2024-12-13T03:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emraclidine-abbvie-net-present-value/ 2024-12-13T03:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giredestrant-roche-net-present-value/ 2024-12-13T03:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-roche-net-present-value/ 2024-12-13T03:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vixarelimab-roche-net-present-value/ 2024-12-13T03:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ov-329-ovid-therapeutics-net-present-value/ 2024-12-13T03:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nmra-511-neumora-therapeutics-net-present-value/ 2024-12-13T03:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pivekimab-sunirine-abbvie-net-present-value/ 2024-12-13T03:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rosnilimab-anaptysbio-net-present-value/ 2024-12-13T03:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-roche-net-present-value/ 2024-12-13T02:56:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-net-present-value-2/ 2024-12-13T02:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/evalstotug-bioatla-net-present-value/ 2024-09-08T16:45:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilebesiran-sodium-roche-net-present-value/ 2024-12-13T02:56:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obefazimod-abivax-net-present-value/ 2024-12-13T02:56:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vamikibart-roche-net-present-value/ 2024-12-13T03:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltrekibart-eli-lilly-and-co-net-present-value/ 2024-12-13T02:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-roche-net-present-value/ 2024-12-13T02:56:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sefaxersen-sodium-roche-net-present-value/ 2024-12-13T02:56:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tavapadon-abbvie-net-present-value/ 2024-12-13T02:56:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvt-3101-roche-net-present-value/ 2024-12-13T02:56:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dirloctocogene-samoparvovec-roche-net-present-value/ 2024-12-13T02:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zatolmilast-shionogi-net-present-value/ 2024-12-13T02:56:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsidolimab-anaptysbio-net-present-value/ 2024-12-13T02:56:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sovleplenib-hutchmed-china-net-present-value/ 2024-12-13T02:56:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astegolimab-roche-net-present-value/ 2024-12-13T02:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tominersen-roche-net-present-value/ 2024-12-13T02:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-588410-shionogi-net-present-value/ 2024-12-13T02:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opregen-roche-net-present-value/ 2024-12-13T02:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prasinezumab-roche-net-present-value/ 2024-12-13T02:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-net-present-value-2/ 2024-12-13T02:55:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-roche-net-present-value/ 2024-12-13T02:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zidesamtinib-nuvalent-net-present-value-2/ 2024-12-13T02:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-net-present-value-2/ 2024-12-13T02:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edg-7500-edgewise-therapeutics-net-present-value-2/ 2024-12-13T02:55:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1117568-neurocrine-biosciences-net-present-value-2/ 2024-12-13T02:55:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delpacibart-etedesiran-avidity-biosciences-net-present-value-2/ 2024-12-13T02:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-net-present-value-2/ 2024-12-13T02:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-roivant-sciences-net-present-value-2/ 2024-12-13T02:55:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dc-806-eli-lilly-and-co-net-present-value-2/ 2024-12-13T02:55:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nanatinostat-valganciclovir-viracta-therapeutics-net-present-value-2/ 2024-12-13T02:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-101-telix-pharmaceuticals-net-present-value-2/ 2024-12-13T02:55:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-er-teva-pharmaceutical-industries-net-present-value-2/ 2024-12-13T02:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsha-102-taysha-gene-therapies-net-present-value-2/ 2024-12-13T02:55:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golcadomide-bristol-myers-squibb-net-present-value-2/ 2024-12-13T02:55:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maridebart-cafraglutide-amgen-net-present-value-2/ 2024-12-13T02:55:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navacaprant-neumora-therapeutics-net-present-value-2/ 2024-12-13T02:55:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-net-present-value-2/ 2024-12-13T02:55:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrasentan-hydrochloride-novartis-net-present-value-2/ 2024-12-13T02:54:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-net-present-value-2/ 2024-12-13T02:55:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disc-0974-disc-medicine-net-present-value-3/ 2024-12-13T02:54:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vax-24-vaxcyte-net-present-value-2/ 2024-12-13T02:54:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sevasemten-edgewise-therapeutics-net-present-value-2/ 2024-12-13T02:54:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alg-009-aligos-therapeutics-net-present-value-2/ 2024-12-13T02:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/disc-0974-disc-medicine-net-present-value-2/ 2024-09-08T16:29:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-397-ideaya-biosciences-net-present-value-2/ 2024-12-13T02:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogens-higher-spinraza-dose-shows-better-efficacy-in-phase-ii-iii-trial/ 2024-09-06T16:34:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/after-failed-fsgs-bid-travere-wins-full-fda-approval-for-filspari-in-igan/ 2024-09-06T16:22:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/investment-opportunities-in-atopic-dermatitis-may-drive-innovation/ 2024-09-06T15:37:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/men-taking-valproate-and-their-partners-warned-to-use-contraception-by-mhra/ 2024-09-06T14:24:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsks-asthma-blockbuster-nucala-secures-win-in-copd-phase-iii-trial/ 2024-09-06T14:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-odd-abdera-neuroendocrine-carcinoma/ 2024-09-06T10:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nimmune-biotherapeutics-precision-medicines/ 2024-09-06T10:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evotec-partner-x-chem/ 2024-09-06T07:58:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-amneal-boruzu/ 2024-09-06T07:54:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-2024-insights-into-rna-as-therapeutic-target-and-tool/ 2024-09-11T20:34:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-2024-new-pacman-ami-trial-analysis-sheds-insights-on-praluent-efficacy/ 2024-09-05T19:55:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/as-mpox-spreads-national-governments-have-a-moral-responsibility-to-help/ 2024-09-06T09:48:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-partners-with-haya-for-lncrna-obesity-target-deal-worth-1bn/ 2024-09-05T15:34:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mrna-moderna-mpox-study-monkey-promise/ 2024-09-05T15:33:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/egenesis-scoops-191m-for-genetically-modified-pig-kidney-transplant-trial/ 2024-09-05T14:39:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy/ 2024-09-05T12:32:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-msd-von-hippel-lindau-disease/ 2024-09-05T10:28:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-to-ban-xylazine/ 2024-09-05T10:22:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/arsenalbio-secures-325m-funds/ 2024-09-11T14:31:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-eva-baricitinib-africa/ 2024-09-05T08:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/combating-pharmaceutical-crime-with-on-dose-authentication/ 2024-10-09T13:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/prokidney-drops-phase-iii-ckd-study-to-focus-on-us-market-and-save-up-to-175m/ 2024-09-04T17:13:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/a-quick-guide-to-transferring-a-commercial-drug-product-to-a-new-fill-finish-cdmo/ 2025-07-03T10:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acepodia-collaborates-with-pfizer-to-advance-antibody-cell-conjugation-therapies/ 2024-09-11T13:30:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/athiras-stock-topples-after-alzheimers-drug-flops-in-phase-ii-iii-trial/ 2024-09-04T15:31:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/actimeds-als-candidate-wins-fda-orphan-drug-designation/ 2024-09-04T14:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-to-optimize-efficiencies-at-site-centric-clinical-trials/ 2024-09-06T12:51:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/primrose-bio-explorna-mrna-therapies/ 2024-09-04T10:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/azuritys-nymalize-fda-approval/ 2024-09-04T09:57:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-keytruda-combo-ec-approval/ 2024-09-04T17:18:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-innovent-ibi363-melanoma/ 2024-09-04T07:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regenxbio-touts-positive-data-for-rare-disease-drug-rgx-121/ 2024-09-03T17:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ocaliva-approval-in-europe-withdrawn-following-data-re-assessment/ 2024-09-05T18:23:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/skyline-wins-orphan-drug-designation-for-retinitis-pigmentosa-gene-therapy/ 2024-09-03T13:35:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-rsv-vaccine-programme-rsv/ 2024-09-03T10:28:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/simcere-zaiming-targetrx-deal/ 2024-09-03T10:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/why-the-importer-of-record-ior-is-vital-in-the-clinical-supply-chain/ 2025-07-15T12:28:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/syntekabio-enamine-drug-developemnt/ 2024-09-04T12:27:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-2024-beta-blocker-treatment-paradigm-shifts-for-myocardial-infarction/ 2024-09-02T16:56:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uae-novo-nordisk-obesity-management/ 2024-09-03T07:58:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-value-of-cns-specific-ecoa-provider-in-clinical-trials/ 2024-09-02T18:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nxera-wins-35m-after-phase-ii-schizophrenia-trial-success/ 2024-09-02T14:51:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novavax-wins-fda-emergency-approval-for-updated-covid-19-vaccine/ 2024-09-02T14:46:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-2024-emerging-data-on-novel-therapeutic-strategies-for-targeting-lipids/ 2024-09-02T14:37:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esc-2024-glp-1ras-lower-cv-risk-meta-analysiw/ 2024-09-04T15:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/phc-licellgrow-prototype-cell-therapy/ 2024-09-04T08:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-onco360-lazcluze/ 2024-09-02T10:33:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-2024-single-pill-hypertension-combo-delivers-positive-results/ 2024-09-02T10:29:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aptose-aml-treatment-development/ 2024-09-02T08:08:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jacobio-pharma-assets-allist/ 2024-09-02T08:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy/ 2024-09-01T23:38:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/diabetes-duration-has-minimal-impact-on-sglt2-inhibitor-efficacy-as-per-new-analysis/ 2024-09-01T17:20:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space/ 2024-09-01T22:53:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/esc-2024-latest-flow-trial-analysis-highlights-how-ozempic-can-benefit-ckd-patients/ 2024-08-30T21:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-targets-generalised-myasthenia-gravis-landscape-with-nipocalimab/ 2024-08-30T18:56:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-congress-amvuttra-data-signals-positive-prospects-in-cardiomyopathy-for-alnylam/ 2024-08-30T21:30:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esc-congress-obesity-drugs-emerge-as-attractive-tool-for-heart-failure-prevention/ 2025-03-05T17:19:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acute-on-chronic-liver-failure-aclf-drugs-in-development/ 2024-09-27T03:12:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atypical-teratoid-rhabdoid-tumor-drugs-in-development/ 2024-09-27T03:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/non-infectious-uveitis-drugs-in-development/ 2024-09-27T03:48:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frontotemporal-dementia-ftd-drugs-in-development/ 2024-09-27T03:28:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/generalized-pustular-psoriasis-gpp-drugs-in-development/ 2024-09-27T03:30:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aromatic-l-amino-acid-decarboxylase-aadc-deficiency-drugs-in-development/ 2024-09-27T03:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpha-thalassaemia-drugs-in-development/ 2024-09-27T03:14:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immunoglobulin-g4-related-disease-igg4-rd-drugs-in-development/ 2024-09-27T03:36:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pulmonary-sarcoidosis-drugs-in-development/ 2024-09-27T03:57:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corneal-dystrophy-drugs-in-development/ 2024-09-27T03:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fuchs-endothelial-corneal-dystrophy-fecd-drugs-in-development/ 2024-09-27T03:29:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm1-gangliosidosis-beta-galactosidase-1-deficiency-drugs-in-development/ 2024-09-27T03:30:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aicardi-goutieres-syndrome-ags-drugs-in-development/ 2024-09-27T03:13:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secondary-acute-myeloid-leukemia-drugs-in-development/ 2024-09-27T04:00:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chemotherapy-induced-oral-mucositis-drugs-in-development/ 2024-09-27T03:20:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-fatigue-syndrome-myalgic-encephalomyelitis-drugs-in-development/ 2024-09-27T03:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primary-sjogren-s-syndrome-drugs-in-development/ 2024-09-27T03:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-traumatic-encephalopathy-cte-drugs-in-development/ 2024-09-27T03:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-granulomatous-disease-drugs-in-development/ 2024-09-27T03:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pancreatic-islet-transplant-rejection-drugs-in-development/ 2024-09-27T03:50:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alport-syndrome-drugs-in-development/ 2024-09-27T03:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melas-syndrome-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-drugs-in-development/ 2024-09-27T03:41:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thrombotic-microangiopathy-drugs-in-development/ 2024-09-27T04:04:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/post-transplant-lymphoproliferative-disorder-drugs-in-development/ 2024-09-27T03:54:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cystinuria-drugs-in-development/ 2024-09-27T03:23:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primary-mediastinal-b-cell-lymphoma-drugs-in-development/ 2024-09-27T03:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/congenital-ichthyosis-drugs-in-development/ 2024-09-27T03:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/progressive-familial-intrahepatic-cholestasis-drugs-in-development/ 2024-09-27T03:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tenosynovial-giant-cell-tumor-drugs-in-development/ 2024-09-27T04:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venezuelan-equine-encephalitis-drugs-in-development/ 2024-09-27T04:07:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepatovirus-infections-drugs-in-development/ 2024-09-27T03:33:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crimean-congo-hemorrhagic-fever-drugs-in-development/ 2024-09-27T03:22:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rubivirus-infections-drugs-in-development/ 2024-09-27T04:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cushing-s-syndrome-drugs-in-development/ 2024-09-27T03:23:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/necrotizing-enterocolitis-drugs-in-development/ 2024-09-27T03:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autism-spectrum-disorder-asd-drugs-in-development/ 2024-09-27T03:16:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rett-syndrome-drugs-in-development/ 2024-09-27T03:59:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corneal-ulcers-drugs-in-development/ 2024-09-27T03:22:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erythromelalgia-drugs-in-development/ 2024-09-27T03:27:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/upper-limb-muscle-spasticity-drugs-in-development/ 2024-09-27T04:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recurrent-glioblastoma-multiforme-gbm-drugs-in-development/ 2024-09-27T03:57:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-adenocarcinoma-of-the-pancreas-drugs-in-development/ 2024-09-27T03:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polyarticular-juvenile-idiopathic-arthritis-pjia-drugs-in-development/ 2024-09-27T03:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giant-cell-arteritis-temporal-arteritis-cranial-arteritis-horton-disease-drugs-in-development/ 2024-09-27T03:30:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/high-grade-glioma-drugs-in-development/ 2024-09-27T03:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/giant-cell-tumor-of-bone-drugs-in-development/ 2024-09-27T03:30:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ductal-carcinoma-in-situ-drugs-in-development/ 2024-09-27T03:25:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemophagocytic-lymphohistiocytosis-drugs-in-development/ 2024-09-27T03:32:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/methylmalonic-acidemia-drugs-in-development/ 2024-09-27T03:43:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gastrointestinal-radiation-toxicity-drugs-in-development/ 2024-09-27T03:29:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ductal-carcinoma-drugs-in-development/ 2024-09-27T03:25:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/non-small-cell-lung-carcinoma-drugs-in-development/ 2024-09-27T03:48:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muscle-atrophy-drugs-in-development/ 2024-09-27T03:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pulmonary-inflammation-drugs-in-development/ 2024-09-27T03:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recurrent-head-and-neck-squamous-cell-carcinoma-drugs-in-development/ 2024-09-27T03:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/persistent-corneal-epithelial-defects-drugs-in-development/ 2024-09-27T03:52:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corneal-edema-drugs-in-development/ 2024-09-27T03:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cartilage-degeneration-drugs-in-development/ 2024-09-27T03:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocular-melanoma-drugs-in-development/ 2024-09-27T03:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-biliary-tract-cancer-drugs-in-development/ 2024-09-27T03:42:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-thromboembolic-pulmonary-hypertension-drugs-in-development/ 2024-09-27T03:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amyloid-cardiomyopathy-drugs-in-development/ 2024-09-27T03:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-bile-duct-cancer-drugs-in-development/ 2024-09-27T03:42:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/social-anxiety-disorder-sad-social-phobia-drugs-in-development/ 2024-09-27T04:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opium-withdrawal-syndrome-drugs-in-development/ 2024-09-27T03:49:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cutaneous-lupus-erythematosus-drugs-in-development/ 2024-09-27T03:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/homozygous-familial-hypercholesterolemia-hofh-drugs-in-development/ 2024-09-27T03:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrenomyeloneuropathy-amn-drugs-in-development/ 2024-09-27T03:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/binge-eating-disorder-drugs-in-development/ 2024-09-27T03:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relapsed-chronic-lymphocytic-leukemia-cll-drugs-in-development/ 2024-09-27T03:58:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/refractory-chronic-lymphocytic-leukemia-cll-drugs-in-development/ 2024-09-27T03:58:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/subacute-cutaneous-lupus-erythematosus-scle-drugs-in-development/ 2024-09-27T04:02:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-cutaneous-lupus-erythematosus-ccle-discoid-lupus-erythematosus-dle-drugs-in-development/ 2024-09-27T03:20:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-transitional-urothelial-tract-cancer-drugs-in-development/ 2024-09-27T03:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/community-acquired-bacterial-pneumonia-drugs-in-development/ 2024-09-27T03:22:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primary-hyperoxaluria-drugs-in-development/ 2024-09-27T03:55:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/haemophilus-influenzae-type-b-infections-drugs-in-development/ 2024-09-27T03:31:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/charcot-marie-tooth-disease-type-i-a-drugs-in-development/ 2024-09-27T03:19:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/charcot-marie-tooth-disease-type-ii-drugs-in-development/ 2024-09-27T03:19:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niemann-pick-disease-type-b-acid-sphingomyelinase-deficiency-drugs-in-development/ 2024-09-27T03:47:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niemann-pick-disease-type-c-drugs-in-development/ 2024-09-27T03:47:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relapsing-multiple-sclerosis-rms-drugs-in-development/ 2024-09-27T03:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/uremic-renal-pruritus-drugs-in-development/ 2024-09-27T04:06:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kidney-fibrosis-drugs-in-development/ 2024-09-27T03:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peripheral-t-cell-lymphomas-ptcl-drugs-in-development/ 2024-09-27T03:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cystitis-drugs-in-development/ 2024-09-27T03:23:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/membranous-glomerulonephritis-drugs-in-development/ 2024-09-27T03:41:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/infectious-diarrhea-drugs-in-development/ 2024-09-27T03:36:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/post-operative-nausea-and-vomiting-drugs-in-development/ 2024-09-27T03:54:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bladder-carcinoma-drugs-in-development/ 2024-09-27T03:17:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atypical-hemolytic-uremic-syndrome-nondiarrhea-associated-hemolytic-uremic-syndrome-drugs-in-development/ 2024-09-27T03:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pulmonary-radiation-toxicity-drugs-in-development/ 2024-09-27T03:56:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/musculoskeletal-inflammation-drugs-in-development/ 2024-09-27T03:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corneal-graft-rejection-drugs-in-development/ 2024-09-27T03:22:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pleural-effusion-drugs-in-development/ 2024-09-27T03:53:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/myxoid-liposarcoma-drugs-in-development/ 2024-09-27T03:45:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/urethral-cancer-drugs-in-development/ 2024-09-27T04:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/non-rhabdomyosarcoma-drugs-in-development/ 2024-09-27T03:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liposarcoma-drugs-in-development/ 2024-09-27T03:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-ovarian-cancer-drugs-in-development/ 2024-09-27T03:42:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-renal-cell-carcinoma-drugs-in-development/ 2024-09-27T03:42:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clostridioides-difficile-infections-clostridium-difficile-associated-disease-drugs-in-development/ 2024-09-27T03:21:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bone-tumor-drugs-in-development/ 2024-09-27T03:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gaucher-disease-type-iii-drugs-in-development/ 2024-09-27T03:29:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precocious-puberty-drugs-in-development/ 2024-09-27T03:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cognitive-impairment-drugs-in-development/ 2024-09-27T03:21:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gaucher-disease-type-i-drugs-in-development/ 2024-09-27T03:29:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anaplastic-large-cell-lymphoma-alcl-drugs-in-development/ 2024-09-27T03:14:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cutaneous-angiosarcoma-drugs-in-development/ 2024-09-27T03:23:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/infantile-spasm-west-syndrome-drugs-in-development/ 2024-09-27T03:36:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyperammonemia-drugs-in-development/ 2024-09-27T03:34:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhino-conjunctivitis-drugs-in-development/ 2024-09-27T03:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/interstitial-lung-fibrosis-drugs-in-development/ 2024-09-27T03:37:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/malignant-pleural-mesothelioma-drugs-in-development/ 2024-09-27T03:40:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acral-lentiginous-melanoma-drugs-in-development/ 2024-09-27T03:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/secondary-cns-lymphoma-drugs-in-development/ 2024-09-27T04:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neurofibromatoses-type-ii-drugs-in-development/ 2024-09-27T03:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corrosive-esophagitis-erosive-esophagitis-drugs-in-development/ 2024-09-27T03:22:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cutaneous-mycosis-drugs-in-development/ 2024-09-27T03:23:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemangiomas-drugs-in-development/ 2024-09-27T03:32:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emesis-vomiting-drugs-in-development/ 2024-09-27T03:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bacterial-sepsis-drugs-in-development/ 2024-09-27T03:17:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neisseria-meningitidis-infections-drugs-in-development/ 2024-09-27T03:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acute-opioid-overdosage-drugs-in-development/ 2024-09-27T03:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mycobacterium-avium-infections-drugs-in-development/ 2024-09-27T03:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/posterior-uveitis-drugs-in-development/ 2024-09-27T03:54:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intermediate-uveitis-drugs-in-development/ 2024-09-27T03:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retinopathy-of-prematurity-drugs-in-development/ 2024-09-27T03:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anterior-uveitis-drugs-in-development/ 2024-09-27T03:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viral-keratitis-drugs-in-development/ 2024-09-27T04:07:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dry-atrophic-macular-degeneration-drugs-in-development/ 2024-09-27T03:25:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/non-proliferative-diabetic-retinopathy-npdr-drugs-in-development/ 2024-09-27T03:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acute-promyelocytic-leukemia-drugs-in-development/ 2024-09-27T03:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/febrile-neutropenia-drugs-in-development/ 2024-09-27T03:28:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sudoriferous-sweat-gland-disorders-drugs-in-development/ 2024-09-27T04:03:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maple-syrup-urine-disease-drugs-in-development/ 2024-09-27T03:41:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/subacute-necrotizing-encephalomyelopathy-leigh-disease-drugs-in-development/ 2024-09-27T04:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hypertrophic-scars-drugs-in-development/ 2024-09-27T03:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/homocystinuria-drugs-in-development/ 2024-09-27T03:33:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autoimmune-encephalitis-post-infectious-drugs-in-development/ 2024-09-27T03:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/traumatic-spinal-cord-injury-drugs-in-development/ 2024-09-27T04:05:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vascular-dementias-drugs-in-development/ 2024-09-27T04:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eastern-equine-encephalitis-drugs-in-development/ 2024-09-27T03:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-bronchitis-drugs-in-development/ 2024-09-27T03:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mucopolysaccharidosis-drugs-in-development/ 2024-09-27T03:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anal-fistula-drugs-in-development/ 2024-09-27T03:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yellow-fever-drugs-in-development/ 2024-09-27T04:08:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duodenal-cancer-drugs-in-development/ 2024-09-27T03:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gastrointestinal-fistula-drugs-in-development/ 2024-09-27T03:29:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cardiomyopathy-drugs-in-development/ 2024-09-27T03:19:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resistant-hypertension-drugs-in-development/ 2024-09-27T03:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/measles-drugs-in-development/ 2024-09-27T03:41:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spasmodic-torticollis-cervical-dystonia-drugs-in-development/ 2024-09-27T04:02:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/klebsiella-pneumoniae-infections-drugs-in-development/ 2024-09-27T03:38:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/japanese-encephalitis-drugs-in-development/ 2024-09-27T03:37:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ai-challenges-precision-personalised-medicine/ 2024-08-30T14:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peanut-allergy-drugs-in-development/ 2024-09-27T03:51:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allergic-rhino-conjunctivitis-drugs-in-development/ 2024-09-27T03:14:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/premature-ovarian-failure-drugs-in-development/ 2024-09-27T03:55:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smoking-cessation-drugs-in-development/ 2024-09-27T04:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nematodal-round-worm-infections-drugs-in-development/ 2024-09-27T03:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepatitis-d-drugs-in-development/ 2024-09-27T03:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zygomycosis-mucormycosis-drugs-in-development/ 2024-09-27T04:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chagas-disease-american-trypanosomiasis-drugs-in-development/ 2024-09-27T03:19:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/burkholderia-infections-drugs-in-development/ 2024-09-27T03:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vulvovaginal-candidiasis-drugs-in-development/ 2024-09-27T04:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/goiter-drugs-in-development/ 2024-09-27T03:30:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acinetobacter-infections-drugs-in-development/ 2024-09-27T03:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrenoleukodystrophy-x-linked-adrenoleukodystrophy-x-ald-drugs-in-development/ 2024-09-27T03:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemoglobinopathies-drugs-in-development/ 2024-09-27T03:32:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aortic-valve-diseases-drugs-in-development/ 2024-09-27T03:15:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemochromatosis-drugs-in-development/ 2024-09-27T03:32:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vasomotor-symptoms-of-menopause-hot-flashes-drugs-in-development/ 2024-09-27T04:07:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/post-partum-depression-maternal-depression-postnatal-depression-drugs-in-development/ 2024-09-27T03:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adenocarcinoma-drugs-in-development/ 2024-09-27T03:13:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/herpetic-keratitis-drugs-in-development/ 2024-09-27T03:33:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paraganglioma-glomus-jugulare-tumor-drugs-in-development/ 2024-09-27T03:51:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/leiomyoma-drugs-in-development/ 2024-09-27T03:38:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muscle-spasm-drugs-in-development/ 2024-09-27T03:44:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rheumatic-disorders-drugs-in-development/ 2024-09-27T03:59:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/global-calcium-hit-with-form-483-after-indian-factory-inspection/ 2024-08-30T14:38:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mycoses-drugs-in-development/ 2024-09-27T03:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xerostomia-drugs-in-development/ 2024-09-27T04:08:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blood-coagulation-drugs-in-development/ 2024-09-27T03:18:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polymyositis-drugs-in-development/ 2024-09-27T03:53:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hypersecretory-conditions-drugs-in-development/ 2024-09-27T03:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mucopolysaccharidosis-vi-mps-vi-maroteaux-lamy-syndrome-drugs-in-development/ 2024-09-27T03:43:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/encephalitis-drugs-in-development/ 2024-09-27T03:26:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bronchiolitis-obliterans-drugs-in-development/ 2024-09-27T03:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mixed-dyslipidemia-drugs-in-development/ 2024-09-27T03:43:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cystic-fibrosis-drugs-in-development/ 2024-09-27T03:23:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/laryngeal-cancer-drugs-in-development/ 2024-09-27T03:38:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paranasal-sinus-and-nasal-cavity-cancer-drugs-in-development/ 2024-09-27T03:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepatitis-e-drugs-in-development/ 2024-09-27T03:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/respiratory-distress-syndrome-drugs-in-development/ 2024-09-27T03:58:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bronchiolitis-drugs-in-development/ 2024-09-27T03:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepatobiliary-system-tumor-drugs-in-development/ 2024-09-27T03:33:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bacillary-dysentery-shigellosis-drugs-in-development/ 2024-09-27T03:16:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peritoneal-tumor-drugs-in-development/ 2024-09-27T03:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esophageal-diseases-drugs-in-development/ 2024-09-27T03:27:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esophagitis-drugs-in-development/ 2024-09-27T03:27:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eosinophilic-esophagitis-drugs-in-development/ 2024-09-27T03:26:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cholestasis-drugs-in-development/ 2024-09-27T03:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enterocolitis-drugs-in-development/ 2024-09-27T03:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enteritis-drugs-in-development/ 2024-09-27T03:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonic-clonic-grand-mal-seizure-drugs-in-development/ 2024-08-30T14:26:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hypersomnia-drugs-in-development/ 2024-09-27T03:35:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sensory-disorders-drugs-in-development/ 2024-09-27T04:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acute-ischemic-stroke-drugs-in-development/ 2024-09-27T03:12:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tay-sachs-disease-drugs-in-development/ 2024-09-27T04:03:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/generalized-seizures-drugs-in-development/ 2024-09-27T03:30:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pre-eclampsia-drugs-in-development/ 2024-09-27T03:54:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/portal-hypertension-drugs-in-development/ 2024-08-30T14:24:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/raynauds-disease-drugs-in-development/ 2024-09-27T03:57:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronary-artery-disease-cad-ischemic-heart-disease-drugs-in-development/ 2025-03-05T15:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hemorrhagic-shock-drugs-in-development/ 2024-09-27T03:32:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vascular-injury-drugs-in-development/ 2024-09-27T04:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cryopyrin-associated-periodic-syndromes-drugs-in-development/ 2024-09-27T03:22:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/juvenile-rheumatoid-arthritis-drugs-in-development/ 2024-08-30T14:22:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wilms-tumor-nephroblastoma-drugs-in-development/ 2024-09-27T04:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plasma-cell-neoplasm-drugs-in-development/ 2024-09-27T03:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hematopoietic-stem-cell-transplantation-drugs-in-development/ 2024-08-30T14:21:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/overactive-bladder-drugs-in-development/ 2024-09-27T03:50:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ependymoma-drugs-in-development/ 2024-09-27T03:26:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cutaneous-t-cell-lymphoma-drugs-in-development/ 2024-09-27T03:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-drugs-in-development/ 2024-09-27T04:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/skin-and-soft-tissue-infections-drugs-in-development/ 2024-09-27T04:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gastroenteritis-drugs-in-development/ 2024-09-27T03:29:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lipid-storage-disorders-lipidoses-drugs-in-development/ 2024-09-27T03:39:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tachycardia-tachyarrhythmias-drugs-in-development/ 2024-09-27T04:03:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narcolepsy-drugs-in-development/ 2024-09-27T03:45:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/addictive-disorders-drugs-in-development/ 2024-09-27T03:13:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dysmenorrhea-drugs-in-development/ 2024-08-30T14:18:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrophic-vaginitis-vaginal-atrophy-vulvovaginal-atrophy-urogenital-atrophy-drugs-in-development/ 2024-09-27T03:16:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hypotension-drugs-in-development/ 2024-09-27T03:35:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nonmelanomatous-skin-cancer-drugs-in-development/ 2024-09-27T03:48:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stomatitis-sore-mouth-drugs-in-development/ 2024-09-27T04:02:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/choroidal-neovascularization-drugs-in-development/ 2024-09-27T03:20:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/major-depressive-disorder-drugs-in-development/ 2024-09-27T03:40:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primary-systemic-amyloidosis-drugs-in-development/ 2024-09-27T03:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/heredofamilial-amyloidosis-drugs-in-development/ 2024-09-27T03:33:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meningioma-drugs-in-development/ 2024-09-27T03:41:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vulvar-cancer-drugs-in-development/ 2024-09-27T04:08:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dystonia-drugs-in-development/ 2024-09-27T03:25:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/urinary-tract-infections-drugs-in-development/ 2024-09-27T04:06:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/west-nile-virus-infections-drugs-in-development/ 2024-09-27T04:08:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-papillomavirus-infections-drugs-in-development/ 2024-09-27T03:34:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fistula-drugs-in-development/ 2024-09-27T03:28:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pouchitis-drugs-in-development/ 2024-09-27T03:54:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fecal-incontinence-drugs-in-development/ 2024-09-27T03:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/metastatic-hepatocellular-carcinoma-hcc-drugs-in-development/ 2024-09-27T03:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bronchitis-drugs-in-development/ 2024-09-27T03:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radiation-toxicity-radiation-sickness-acute-radiation-syndrome-drugs-in-development/ 2024-09-27T03:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhinitis-drugs-in-development/ 2024-09-27T03:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/equine-encephalitis-drugs-in-development/ 2024-09-27T03:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cachexia-drugs-in-development/ 2024-09-27T03:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chronic-urticaria-or-hives-drugs-in-development/ 2024-09-27T03:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epidermolysis-bullosa-drugs-in-development/ 2024-09-27T03:26:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vitiligo-drugs-in-development/ 2024-09-27T04:07:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tardive-dyskinesia-drugs-in-development/ 2024-09-27T04:03:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyperlipidemia-drugs-in-development/ 2024-09-27T03:34:45+00:00 daily 0.2